Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gynecology
Simultaneous blockade of Bcl-2 and DNA repair staunches ovarian cancer growth
December 28th, 2004
Simultaneous blockade of Bcl-2 and DNA repair staunches ovarian cancer growth. According to a study from England, "temozolomide is an alkylating agent that mediates its cytotoxic effects via O-6-methylguanine (O-6-meG) adducts in DNA. O-6-alkylguanine-DNA-alkyltransferase (MGMT) can repair such adducts and therefore constitutes a major resistance mechanism to the drug. MGMT activity can be attenuated in vitro and in vivo by the pseudosubstrate O-6-(4-bromothenyl)guanine (PaTrin-2, Patrin, Lomeguatrib), which in clinical trials is in combination with temozolomide." "Resistance to cytotoxic agents can also be mediated by the Bcl-2 protein, which...
Source: Cancer Weekly (2004-12-28)
|
